Outcome of the Meeting of Board of Directors held on Thursday, November 06, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and in line with its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Genpharmasec approved its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, along with the auditor's limited review report. Standalone revenue from operations surged to Rs. 4,549.94 lakhs in H1 FY26 from Rs. 1,250.85 lakhs in H1 FY25 (over 260% growth), while standalone profit for the period rose to Rs. 237.51 lakhs from Rs. 158.64 lakhs (~50% growth). Consolidated results include newly acquired subsidiary Derren Healthcare Pvt Ltd (70% stake completed July 25, 2025), which reported a net loss of Rs. 171.60 lakhs since acquisition. The auditor Bilimoria Mehta & Co. gave an unmodified (clean) review opinion, noting that the previous (erstwhile) auditor had reviewed the Q1 FY26 results — indicating a mid-year change of statutory auditor.
Sharp revenue growth is driven largely by the new Derren Healthcare subsidiary consolidation and increased trading activity, not just organic expansion. Consolidated profitability is muted by the subsidiary's losses and acquisition-related costs. The change in statutory auditor mid-year is worth monitoring, though the clean review report limits immediate concern.